Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey.

IF 1.8 Q3 ENDOCRINOLOGY & METABOLISM Thyroid Research Pub Date : 2022-03-05 DOI:10.1186/s13044-022-00121-9
Maria-Cristina Burlacu, Roberto Attanasio, Laszlo Hegedüs, Endre V Nagy, Enrico Papini, Petros Perros, Kiswendsida Sawadogo, Marie Bex, Bernard Corvilain, Chantal Daumerie, Brigitte Decallonne, Damien Gruson, Bruno Lapauw, Rodrigo Moreno Reyes, Patrick Petrossians, Kris Poppe, Annick Van den Bruel, David Unuane
{"title":"Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey.","authors":"Maria-Cristina Burlacu, Roberto Attanasio, Laszlo Hegedüs, Endre V Nagy, Enrico Papini, Petros Perros, Kiswendsida Sawadogo, Marie Bex, Bernard Corvilain, Chantal Daumerie, Brigitte Decallonne, Damien Gruson, Bruno Lapauw, Rodrigo Moreno Reyes, Patrick Petrossians, Kris Poppe, Annick Van den Bruel, David Unuane","doi":"10.1186/s13044-022-00121-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypothyroidism is a topic that continues to provoke debate and controversy with regards to specific indications, type of thyroid hormone substitution and efficacy. We investigated the use of thyroid hormones in clinical practice in Belgium, a country where currently only levothyroxine (LT4) tablet formulations are available.</p><p><strong>Method: </strong>Members of the Belgian Endocrine Society were invited to respond to an online questionnaire. Results were compared with those from other THESIS surveys.</p><p><strong>Results: </strong>Eighty (50%) of the invited 160 individuals, completed the questionnaire. LT4 was the first treatment of choice for all respondents. As secondary choice, some also prescribed liothyronine (LT3) and LT4 + LT3 combinations (2 and 7 respondents, respectively). Besides hypothyroidism, 34 and 50% of respondents used thyroid hormones for infertile euthyroid TPOAb positive women and the treatment of a growing non-toxic goiter, respectively. Had alternative formulations of LT4 to tablets been available (soft gel or liquid L-T4), 2 out of 80 (2.5%) participants would consider them for patients achieving biochemical euthyroidism but remaining symptomatic. This proportion was higher in case of unexplained poor biochemical control of hypothyroidism (13.5%) and in patients with celiac disease or malabsorption or interfering drugs (10%). In symptomatic euthyroid patients, 20% of respondents would try combined LT4 + LT3 treatment. Psychosocial factors were highlighted as the main contributors to persistent symptoms.</p><p><strong>Conclusions: </strong>LT4 tablets is the preferred treatment for hypothyroidism in Belgium. A minority of the respondents would try combined LT4 + LT3 in symptomatic but biochemically euthyroid patients. Thyroid hormones are prescribed for euthyroid infertile women with thyroid autoimmunity and patients with non-toxic goiter, a tendency noted in other European countries, despite current evidence of lack of benefit.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":" ","pages":"3"},"PeriodicalIF":1.8000,"publicationDate":"2022-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897091/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13044-022-00121-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hypothyroidism is a topic that continues to provoke debate and controversy with regards to specific indications, type of thyroid hormone substitution and efficacy. We investigated the use of thyroid hormones in clinical practice in Belgium, a country where currently only levothyroxine (LT4) tablet formulations are available.

Method: Members of the Belgian Endocrine Society were invited to respond to an online questionnaire. Results were compared with those from other THESIS surveys.

Results: Eighty (50%) of the invited 160 individuals, completed the questionnaire. LT4 was the first treatment of choice for all respondents. As secondary choice, some also prescribed liothyronine (LT3) and LT4 + LT3 combinations (2 and 7 respondents, respectively). Besides hypothyroidism, 34 and 50% of respondents used thyroid hormones for infertile euthyroid TPOAb positive women and the treatment of a growing non-toxic goiter, respectively. Had alternative formulations of LT4 to tablets been available (soft gel or liquid L-T4), 2 out of 80 (2.5%) participants would consider them for patients achieving biochemical euthyroidism but remaining symptomatic. This proportion was higher in case of unexplained poor biochemical control of hypothyroidism (13.5%) and in patients with celiac disease or malabsorption or interfering drugs (10%). In symptomatic euthyroid patients, 20% of respondents would try combined LT4 + LT3 treatment. Psychosocial factors were highlighted as the main contributors to persistent symptoms.

Conclusions: LT4 tablets is the preferred treatment for hypothyroidism in Belgium. A minority of the respondents would try combined LT4 + LT3 in symptomatic but biochemically euthyroid patients. Thyroid hormones are prescribed for euthyroid infertile women with thyroid autoimmunity and patients with non-toxic goiter, a tendency noted in other European countries, despite current evidence of lack of benefit.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲状腺功能减退和甲状腺功能正常患者甲状腺激素的使用:比利时专家的THESIS*调查THESIS:欧洲专家对甲状腺功能减退的治疗:一项国际调查
背景:甲状腺功能减退症是一个持续引发争论和争议的话题,涉及到具体适应症、甲状腺激素替代的类型和疗效。我们调查了比利时临床实践中甲状腺激素的使用情况,该国目前只有左旋甲状腺素(LT4)片剂配方。方法:邀请比利时内分泌学会会员填写在线问卷。结果与其他THESIS调查结果进行了比较。结果:被邀请的160人中有80人(50%)完成了问卷调查。LT4是所有受访者的首选治疗方法。作为次要选择,一些人还开了碘甲状腺原氨酸(LT3)和LT4 + LT3组合(分别为2和7名受访者)。除了甲状腺功能减退症,34%和50%的受访者分别使用甲状腺激素治疗不育甲状腺功能正常的TPOAb阳性妇女和治疗日益严重的无毒甲状腺肿。如果有替代片剂的LT4制剂(软凝胶或液体L-T4), 80名参与者中有2名(2.5%)会考虑将其用于实现生化甲状腺功能亢进但仍有症状的患者。在不明原因的甲状腺功能减退症生化控制不良的情况下(13.5%)和乳糜泻或吸收不良或干扰药物的患者中(10%),这一比例更高。在有症状的甲状腺功能正常患者中,20%的受访者会尝试LT4 + LT3联合治疗。强调社会心理因素是造成持续症状的主要因素。结论:LT4片是比利时治疗甲状腺功能减退的首选药物。少数受访者会在有症状但生化功能正常的患者中尝试LT4 + LT3联合治疗。甲状腺激素被用于甲状腺自身免疫的甲状腺功能正常的不孕妇女和无毒甲状腺肿患者,尽管目前的证据表明缺乏益处,但在其他欧洲国家也有这种趋势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thyroid Research
Thyroid Research Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
3.10
自引率
4.50%
发文量
21
审稿时长
8 weeks
期刊最新文献
Abstracts of the EUGOGO Global TED Forum 2025. Multidisciplinary management of thyroid eye disease (TED) in patients with latent tuberculosis or chronic hepatitis B. Pediatric Graves' orbitopathy: TRAb and FT-3 are also prognostic factors in children-A tertiary center study. Prediction of thyroid nodule properties and potential for malignant metastasis based on tumor pH. Bilaterality in papillary thyroid carcinoma: long-term outcomes and predictive factors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1